Tremelimumab in Melanoma
| Drug class | Target | Agent | Diseases | Line of Therapy | Status | Source |
|---|---|---|---|---|---|---|
| CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody | CTLA-4 | tremelimumab | melanoma | metastatic | Trials complete with results | Ribas et al. 2013 |
The CTLA-4 inhibitor tremelimumab has previously been investigated in patients with melanoma. The only phase III clinical trial of tremelimumab to date was published in 2013, and it failed to show a statistically significant improvement in overall survival when patients with previously untreated metastatic melanoma were treated with tremelimumab compared to standard chemotherapy alone (NCT00257205; Ribas et al. 2013).
| Reference | Study Type / Phase | Line of Treatment | Treatment Agent | Mutation Status | # Patients in Study | Response Rate | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|---|
| Ribas et al. 2013 | Phase III | 1st | tremelimumab | 328 | 10.7% | 20.3 (6-month PFS) | 12.6 | |
| dacarbazine or temozolamide | 327 | 9.8% | 18.1 (6-month PFS) | 10.7 |
Contributors: Wade T. Iams, M.D., Douglas Johnson, M.D., Christine M. Lovly, M.D., Ph.D.
Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.mycancergenome.org/content/molecular-medicine/c49085-melanoma/ (Updated February 10).
Last Updated: June 24, 2015